» Articles » PMID: 36046716

Prospects of Malaria Vaccination in Nigeria: Anticipated Challenges and Lessons from Previous Vaccination Campaigns

Abstract

Malaria is a severe public health issue in Nigeria, with higher morbidity and mortality rates than any other country. An estimated 100 million malaria cases and over 300,000 deaths are recorded yearly in Nigeria. Vaccination is an effective strategy in combating and eliminating infectious diseases such as malaria, thus, the deployment of a prospective malaria vaccine in Nigeria offers hope to the country's health sector. However, vaccination programmes face challenges, particularly in communities that are difficult to reach geographically or culturally, and these obstacles can only be overcome through continued international, national, and individual commitment. There is a need for expanded and continuous public health information, education, and communication particularly on contemporary health issues such as malaria and vaccination hesitancy. This will enable easier implementation and compliance to strategies for the sustainable control and eventual elimination of malaria. This article highlights some of the lessons learned from previous vaccination programs in Nigeria and how the insight gotten can be pivotal in ensuring the success of a prospective malaria vaccination programme in Nigeria.

Citing Articles

The Importance of Lassa Fever and Its Disease Management in West Africa.

Reyna R, Littlefield K, Shehu N, Makishima T, Maruyama J, Paessler S Viruses. 2024; 16(2).

PMID: 38400041 PMC: 10892767. DOI: 10.3390/v16020266.


Unlocking the potential of novel RTS, S/AS01, and R21/Matrix-M™ malaria vaccines in African nations.

Oduoye M, Haider M, Marsool M, Kareem M, Adedayo A, Abdulkarim A Health Sci Rep. 2024; 7(1):e1797.

PMID: 38186933 PMC: 10766872. DOI: 10.1002/hsr2.1797.


Prediction of malaria positivity using patients' demographic and environmental features and clinical symptoms to complement parasitological confirmation before treatment.

Ojurongbe T, Afolabi H, Bashiru K, Sule W, Akinde S, Ojurongbe O Trop Dis Travel Med Vaccines. 2023; 9(1):24.

PMID: 38098124 PMC: 10722830. DOI: 10.1186/s40794-023-00208-7.


Safety and antimalarial therapeutic index of alkaloid-rich extract of Schumach. & Thonn. in mice.

Okom S, Ojugbeli E, Okpoghono J, Onyesom I Heliyon. 2023; 9(12):e23078.

PMID: 38076132 PMC: 10703837. DOI: 10.1016/j.heliyon.2023.e23078.


Monkeypox vaccination in the global south: Fighting a war without a weapon.

Ogunkola I, Abiodun O, Bale B, Elebesunu E, Ujam S, Umeh I Clin Epidemiol Glob Health. 2023; 22:101313.

PMID: 37220529 PMC: 10195808. DOI: 10.1016/j.cegh.2023.101313.

References
1.
Kuehn B . Vaccine Development Is Charting a New Path in Malaria Control. JAMA. 2022; 327(6):510-512. DOI: 10.1001/jama.2021.20627. View

2.
Arama C, Troye-Blomberg M . The path of malaria vaccine development: challenges and perspectives. J Intern Med. 2014; 275(5):456-66. DOI: 10.1111/joim.12223. View

3.
Arita I, Nakane M . Road map for polio eradication--establishing the link with Millennium Development Goal no. 4 for child survival. Jpn J Infect Dis. 2008; 61(3):169-74. View

4.
Patouillard E, Griffin J, Bhatt S, Ghani A, Cibulskis R . Global investment targets for malaria control and elimination between 2016 and 2030. BMJ Glob Health. 2017; 2(2):e000176. PMC: 5584487. DOI: 10.1136/bmjgh-2016-000176. View

5.
Cherubini A, Del Signore S, Ouslander J, Semla T, Michel J . Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010; 58(9):1791-6. DOI: 10.1111/j.1532-5415.2010.03032.x. View